The DOI matches its Crossref record; 177 of the 177 references it cites were found in a registry or an index.
Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs
Open accessAbstract
Of late, targeted protein degradation (TPD) has surfaced as a novel and innovative chemical tool and therapeutic modality. By co-opting protein degradation pathways, TPD facilitates complete removal of the protein molecules from within or outside the cell. While the pioneering Proteolysis-Targeting Chimera (PROTAC) technology and molecular glues hijack the ubiquitin-proteasome system, newer modalities co-opt autophagy or the endo-lysosomal pathway. Using this mechanism, TPD is posited to largely expand the druggable space far beyond small-molecule inhibitors. In this review, we discuss the major advances in TPD, highlight our current understanding, and explore outstanding questions in the field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Autophagy: cellular and molecular mechanisms
Glick, D., Barth, S., & Macleod, K. F. (2010) · The Journal of Pathology · doi:10.1002/path.2697 · Cited by 3,802
Komander, D., & Rape, M. (2012) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060310-170328 · Cited by 3,679 · cited 3×
“Lastly, the E3 adaptor protein facilitates transfer of ubiquitin from the E2 to a lysine residue side chain on the substrate protein (9).”
BackgroundABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Sakamoto, K. M., Kim, K. B., Kumagai, A., Mercurio, F., Crews, C. M., & Deshaies, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141230798 · Cited by 2,609 · cited 1×
“In 2001, our laboratory, in collaboration with the Deshaies laboratory, showed that the UPS can be hijacked to control protein degradation (12).”
BackgroundSelf-citationIAP family proteins---suppressors of apoptosis
Deveraux, Q. L., & Reed, J. C. (1999) · Genes & Development · doi:10.1101/gad.13.3.239 · Cited by 2,551
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517 · cited 1×
“In fact, point mutations such as F876L and T877A turn enzalutamide into an agonist (121, 122).”
BackgroundAdapting Proteostasis for Disease Intervention
Balch, W. E., Morimoto, R. I., Dillin, A., & Kelly, J. W. (2008) · Science · doi:10.1126/science.1141448 · Cited by 2,495
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
X-linked IAP is a direct inhibitor of cell-death proteases
Deveraux, Q. L., Takahashi, R., Salvesen, G. S., & Reed, J. C. (1997) · Nature · doi:10.1038/40901 · Cited by 1,955
Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
Krönke, J., Udeshi, N. D., Narla, A., Grauman, P., Hurst, S. N., McConkey, M., Svinkina, T., Heckl, D., Comer, E., Li, X., et al. (2014) · Science · doi:10.1126/science.1244851 · Cited by 1,879
Mechanism of auxin perception by the TIR1 ubiquitin ligase
Tan, X., Calderon-Villalobos, L. I. A., Sharon, M., Zheng, C., Robinson, C. V., Estelle, M., & Zheng, N. (2007) · Nature · doi:10.1038/nature05731 · Cited by 1,688
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer
Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., Coskinas, X., Frydenberg, M., Hague, W. E., Horvath, L. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903835 · Cited by 1,633 · cited 1×
“For instance, enzalutamide is a successful FDA-approved drug that targets castration-resistant prostate cancer via androgen receptor antagonism; however, inevitably resistance occurs (120).”
BackgroundBCL-2 family proteins: changing partners in the dance towards death
Kale, J., Osterlund, E. J., & Andrews, D. W. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.186 · Cited by 1,574
Catalytic in vivo protein knockdown by small-molecule PROTACs
Bondeson, D. P., Mares, A., Smith, I. E. D., Ko, E., Campos, S., Miah, A. H., Mulholland, K. E., Routly, N., Buckley, D. L., Gustafson, J. L., et al. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1858 · Cited by 1,356
Self-citationStructural basis of PROTAC cooperative recognition for selective protein degradation
Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2329 · Cited by 1,242
Lysosome-targeting chimaeras for degradation of extracellular proteins
Banik, S. M., Pedram, K., Wisnovsky, S., Ahn, G., Riley, N. M., & Bertozzi, C. R. (2020) · Nature · doi:10.1038/s41586-020-2545-9 · Cited by 1,199 · cited 2×
“To target extracellular proteins, the Bertozzi lab developed Lysosomal-Targeting Chimeras (LYTACs) (154) (Fig.”
BackgroundBiological and Chemical Approaches to Diseases of Proteostasis Deficiency
Powers, E. T., Morimoto, R. I., Dillin, A., Kelly, J. W., & Balch, W. E. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.114844 · Cited by 1,149
Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
Fischer, E. S., Böhm, K., Lydeard, J. R., Yang, H., Stadler, M. B., Cavadini, S., Nagel, J., Serluca, F., Acker, V., Lingaraju, G. M., et al. (2014) · Nature · doi:10.1038/nature13527 · Cited by 1,141
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4
Lu, J., Qian, Y., Altieri, M., Dong, H., Wang, J., Raina, K., Hines, J., Winkler, J. D., Crew, A. P., Coleman, K., et al. (2015) · Chemistry & Biology · doi:10.1016/j.chembiol.2015.05.009 · Cited by 1,140
Self-citationThe dTAG system for immediate and target-specific protein degradation
Nabet, B., Roberts, J. M., Buckley, D. L., Paulk, J., Dastjerdi, S., Yang, A., Leggett, A. L., Erb, M. A., Lawlor, M. A., Souza, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0021-8 · Cited by 1,118 · cited 1×
“Furthermore, the establishment of Halo-PROTACs (25) and dTAG (26, 27) systems, which allow targeted degradation of HaloTag7 and FKBP fusion proteins respectively, has allowed for degradation of proteins without established ligands.”
BackgroundProteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
Burslem, G. M., & Crews, C. M. (2020) · Cell · doi:10.1016/j.cell.2019.11.031 · Cited by 1,079
Self-citationLessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead
Bondeson, D. P., Smith, B. E., Burslem, G. M., Buhimschi, A. D., Hines, J., Jaime-Figueroa, S., Wang, J., Hamman, B. D., Ishchenko, A., & Crews, C. M. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.010 · Cited by 923
Self-citationPROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer
Raina, K., Lu, J., Qian, Y., Altieri, M., Gordon, D., Rossi, A. M. K., Wang, J., Chen, X., Dong, H., Siu, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521738113 · Cited by 852
Self-citationThe evolution of thalidomide and its IMiD derivatives as anticancer agents
Bartlett, J. B., Dredge, K., & Dalgleish, A. G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1323 · Cited by 809
PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future
Pettersson, M., & Crews, C. M. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.01.002 · Cited by 800
Self-citationAnticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
Han, T., Goralski, M., Gaskill, N., Capota, E., Kim, J., Ting, T. C., Xie, Y., Williams, N. S., & Nijhawan, D. (2017) · Science · doi:10.1126/science.aal3755 · Cited by 762
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0668-z · Cited by 688
The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
Burslem, G. M., Smith, B. E., Lai, A. C., Jaime-Figueroa, S., McQuaid, D. C., Bondeson, D. P., Toure, M., Dong, H., Qian, Y., Wang, J., et al. (2018) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.09.009 · Cited by 686
Self-citationAUTACs: Cargo-Specific Degraders Using Selective Autophagy
Takahashi, D., Moriyama, J., Nakamura, T., Miki, E., Takahashi, E., Sato, A., Akaike, T., Itto-Nakama, K., & Arimoto, H. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.09.009 · Cited by 675
Thalidomide: The Tragedy of Birth Defects and the Effective Treatment of Disease
Kim, J. H., & Scialli, A. R. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr088 · Cited by 659
A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo
Bai, L., Zhou, H., Xu, R., Zhao, Y., Chinnaswamy, K., McEachern, D., Chen, J., Yang, C.-Y., Liu, Z., Wang, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.002 · Cited by 652
Schneekloth, A. R., Pucheault, M., Tae, H. S., & Crews, C. M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.114 · Cited by 635
Self-citationHECT and RING finger families of E3 ubiquitin ligases at a glance
Metzger, M. B., Hristova, V. A., & Weissman, A. M. (2012) · Journal of Cell Science · doi:10.1242/jcs.091777 · Cited by 630
Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase
Petzold, G., Fischer, E. S., & Thomä, N. H. (2016) · Nature · doi:10.1038/nature16979 · Cited by 620
Gandhi, A. K., Kang, J., Havens, C. G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M. F., Thakurta, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12708 · Cited by 619
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
Ahn, G., Banik, S. M., Miller, C. L., Riley, N. M., Cochran, J. R., & Bertozzi, C. R. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00770-1 · Cited by 619
Modular PROTAC design for the degradation of oncogenic BCR-ABL
Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime‐Figueroa, S., Ko, E., Hines, J., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507634 · Cited by 618 · cited 1×
“Interestingly, as compared with VHL, the promiscuous CRBN has been shown to be more accepting of neosubstrate degradation thus far (69).”
BackgroundSelf-citationPROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 613
Cleaning house: selective autophagy of organelles
Anding, A. L., & Baehrecke, E. H. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.02.016 · Cited by 576
Buckley, D. L., Van Molle, I., Gareiss, P. C., Tae, H. S., Michel, J., Noblin, D. J., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja209924v · Cited by 569
Self-citationAllele-selective lowering of mutant HTT protein by HTT–LC3 linker compounds
Li, Z., Wang, C., Wang, Z., Zhu, C., Li, J., Sha, T., Ma, L., Gao, C., Yang, Y., Sun, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1722-1 · Cited by 551
Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
Sievers, Q. L., Petzold, G., Bunker, R. D., Renneville, A., Słabicki, M., Liddicoat, B. J., Abdulrahman, W., Mikkelsen, T., Ebert, B. L., & Thomä, N. H. (2018) · Science · doi:10.1126/science.aat0572 · Cited by 537 · cited 8×
“In addition, small structural changes to IMiDs, which cause slight changes in neosubstrate affinity, can result in major differences in target selectivity within cells.”
BackgroundInfluentialYesbolatova, A., Saito, Y., Kitamoto, N., Makino-Itou, H., Ajima, R., Nakano, R., Nakaoka, H., Fukui, K., Gamo, K., Tominari, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19532-z · Cited by 533
A Method for the Acute and Rapid Degradation of Endogenous Proteins
Clift, D., McEwan, W. A., Labzin, L. I., Konieczny, V., Mogessie, B., James, L. C., & Schuh, M. (2017) · Cell · doi:10.1016/j.cell.2017.10.033 · Cited by 531
Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase
Smith, B. E., Wang, S. L., Jaime-Figueroa, S., Harbin, A., Wang, J., Hamman, B. D., & Crews, C. M. (2019) · Nature Communications · doi:10.1038/s41467-018-08027-7 · Cited by 517 · cited 2×
“(103) used a short molecular dynamics (MD) simulation to help explain PROTAC selectivity of p38 isoform degradation.”
BackgroundSelf-citationCellular Strategies of Protein Quality Control
Chen, B., Retzlaff, M., Roos, T., & Frydman, J. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004374 · Cited by 502
An Atg9-containing compartment that functions in the early steps of autophagosome biogenesis
Mari, M., Griffith, J., Rieter, E., Krishnappa, L., Klionsky, D. J., & Reggiori, F. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200912089 · Cited by 491
PROTACs: An Emerging Therapeutic Modality in Precision Medicine
Nalawansha, D. A., & Crews, C. M. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.07.020 · Cited by 490
Self-citationHaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins
Buckley, D. L., Raina, K., Darricarrere, N., Hines, J., Gustafson, J. L., Smith, I. E., Miah, A. H., Harling, J. D., & Crews, C. M. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00442 · Cited by 488
Self-citationElectrophilic PROTACs that degrade nuclear proteins by engaging DCAF16
Zhang, X., Crowley, V. M., Wucherpfennig, T. G., Dix, M. M., & Cravatt, B. F. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0279-5 · Cited by 487
Chemical Genetic Control of Protein Levels: Selective in Vivo Targeted Degradation
Schneekloth, J. S., Fonseca, F. N., Koldobskiy, M., Mandal, A., Deshaies, R., Sakamoto, K., & Crews, C. M. (2004) · Journal of the American Chemical Society · doi:10.1021/ja039025z · Cited by 487
Self-citationMechanism of action of lenalidomide in hematological malignancies
Kotla, V., Goel, S., Nischal, S., Heuck, C., Vivek, K., Das, B., & Verma, A. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-36 · Cited by 467
Beltran, H., Yelensky, R., Frampton, G. M., Park, K., Downing, S. R., MacDonald, T. Y., Jarosz, M., Lipson, D., Tagawa, S. T., Nanus, D. M., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.08.053 · Cited by 454
Targeted Degradation of Oncogenic KRAS G12C by VHL-Recruiting PROTACs
Bond, M. J., Chu, L., Nalawansha, D. A., Li, K., & Crews, C. M. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00411 · Cited by 450
Self-citationThe CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K
Słabicki, M., Kozicka, Z., Petzold, G., Li, Y.-D., Manojkumar, M., Bunker, R. D., Donovan, K. A., Sievers, Q. L., Koeppel, J., Suchyta, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2374-x · Cited by 433 · cited 1×
“correlated drug sensitivity to mRNA levels of E3 ligase components to identify molecules that may act through a degradation mechanism of action (148).”
BackgroundHarnessing the anti-cancer natural product nimbolide for targeted protein degradation
Spradlin, J. N., Hu, X., Ward, C. C., Brittain, S. M., Jones, M. D., Ou, L., To, M., Proudfoot, A., Ornelas, E., Woldegiorgis, M., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0304-8 · Cited by 432
Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation
Sakamoto, K. M., Kim, K. B., Verma, R., Ransick, A., Stein, B., Crews, C. M., & Deshaies, R. J. (2003) · Molecular & Cellular Proteomics · doi:10.1074/mcp.t300009-mcp200 · Cited by 425
Self-citationDelineating the role of cooperativity in the design of potent PROTACs for BTK
Zorba, A., Nguyen, C., Xu, Y., Starr, J., Borzilleri, K., Smith, J., Zhu, H., Farley, K. A., Ding, W., Schiemer, J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803662115 · Cited by 419
Perilous journey: a tour of the ubiquitin–proteasome system
Kleiger, G., & Mayor, T. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.12.003 · Cited by 409
Itoh, Y., Ishikawa, M., Naito, M., & Hashimoto, Y. (2010) · Journal of the American Chemical Society · doi:10.1021/ja100691p · Cited by 404
Buhimschi, A. D., Armstrong, H. A., Toure, M., Jaime-Figueroa, S., Chen, T. L., Lehman, A. M., Woyach, J. A., Johnson, A. J., Byrd, J. C., & Crews, C. M. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00391 · Cited by 394
Self-citationSPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate
Roy, M. J., Winkler, S., Hughes, S. J., Whitworth, C., Galant, M., Farnaby, W., Rumpel, K., & Ciulli, A. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00092 · Cited by 386
Light-Induced Protein Degradation with Photocaged PROTACs
Xue, G., Wang, K., Zhou, D., Zhong, H., & Pan, Z. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b06422 · Cited by 377
Rational discovery of molecular glue degraders via scalable chemical profiling
Mayor-Ruiz, C., Bauer, S., Brand, M., Kozicka, Z., Siklos, M., Imrichova, H., Kaltheuner, I. H., Hahn, E., Seiler, K., Koren, A., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0594-x · Cited by 369
Zhang, L., Riley-Gillis, B., Vijay, P., & Shen, Y. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1129 · Cited by 365
Autophagy and the ubiquitin-proteasome system: Collaborators in neuroprotection
Nedelsky, N. B., Todd, P. K., & Taylor, J. P. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.10.002 · Cited by 351
Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4
Maneiro, M., Forte, N., Shchepinova, M. M., Kounde, C. S., Chudasama, V., Baker, J. R., & Tate, E. W. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00285 · Cited by 350 · cited 1×
“The Tate group demonstrated this by coupling a BRD4-targeting PROTAC to trastuzumab, a HER2-targeting antibody (85).”
BackgroundSalami, J., Alabi, S., Willard, R. R., Vitale, N. J., Wang, J., Dong, H., Jin, M., McDonnell, D. P., Crew, A. P., Neklesa, T. K., et al. (2018) · Communications Biology · doi:10.1038/s42003-018-0105-8 · Cited by 349
Self-citationHines, J., Lartigue, S., Dong, H., Qian, Y., & Crews, C. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2918 · Cited by 348
Self-citationSALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate
Matyskiela, M. E., Couto, S., Zheng, X., Lu, G., Hui, J., Stamp, K., Drew, C., Ren, Y., Wang, M., Carpenter, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0129-x · Cited by 338 · cited 1×
“For instance, studies have now clarified that the teratogenicity initially observed was likely due to recruitment of the neosubstrate SALL4 (143).”
BackgroundDantuma, N. P., & Bott, L. C. (2014) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2014.00070 · Cited by 338
Zoppi, V., Hughes, S. J., Maniaci, C., Testa, A., Gmaschitz, T., Wieshofer, C., Koegl, M., Riching, K. M., Daniels, D. L., Spallarossa, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01413 · Cited by 336 · cited 1×
“Furthermore, the linker composition and vector (the direction in which an E3 ligase is recruited to a protein) can play important roles in encouraging or discouraging ternary complex formation (103, 104).”
BackgroundWard, C. C., Kleinman, J. I., Brittain, S. M., Lee, P. S., Chung, C. Y. S., Kim, K., Petri, Y., Thomas, J. R., Tallarico, J. A., McKenna, J. M., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.8b01083 · Cited by 336
PHOTACs enable optical control of protein degradation
Reynders, M., Matsuura, B. S., Bérouti, M., Simoneschi, D., Marzio, A., Pagano, M., & Trauner, D. (2020) · Science Advances · doi:10.1126/sciadv.aay5064 · Cited by 321
Khandia, R., Dadar, M., Munjal, A., Dhama, K., Karthik, K., Tiwari, R., Yatoo, M. I., Iqbal, H. M. N., Singh, K. P., Joshi, S. K., et al. (2019) · Cells · doi:10.3390/cells8070674 · Cited by 314
Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules
Nabet, B., Ferguson, F. M., Seong, B. K. A., Kuljanin, M., Leggett, A. L., Mohardt, M. L., Robichaud, A., Conway, A. S., Buckley, D. L., Mancias, J. D., et al. (2020) · doi:10.1101/2020.03.13.980946 · Cited by 312
Lu, M., Liu, T., Jiao, Q., Ji, J., Tao, M., Liu, Y., You, Q., & Jiang, Z. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.063 · Cited by 310
Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action
Riching, K. M., Mahan, S., Corona, C. R., McDougall, M., Vasta, J. D., Robers, M. B., Urh, M., & Daniels, D. L. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.8b00692 · Cited by 304
Small‐Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α
Buckley, D. L., Gustafson, J. L., Van Molle, I., Roth, A. G., Tae, H. S., Gareiss, P. C., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201206231 · Cited by 302
Self-citationReversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs
Pfaff, P., Samarasinghe, K. T. G., Crews, C. M., & Carreira, E. M. (2019) · ACS Central Science · doi:10.1021/acscentsci.9b00713 · Cited by 301
Self-citationAddressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation
Cromm, P. M., Samarasinghe, K. T. G., Hines, J., & Crews, C. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b08008 · Cited by 293 · cited 1×
“For example,while inhibitionof Focal Adhesion Kinase (FAK) with defactinib inhibits cell division, a defactinib-based PROTAC halted both cell proliferation and cell motility (118).”
BackgroundLight-induced control of protein destruction by opto-PROTAC
Liu, J., Chen, H., Ma, L., He, Z., Wang, D., Liu, Y., Lin, Q., Zhang, T., Gray, N., Kaniskan, H. Ü., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay5154 · Cited by 292
He, Y., Zhang, X., Chang, J., Kim, H.-N., Zhang, P., Wang, Y., Khan, S., Liu, X., Zhang, X., Lv, D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15838-0 · Cited by 280
Exploring Targeted Degradation Strategy for Oncogenic KRASG12C
Zeng, M., Xiong, Y., Safaee, N., Nowak, R. P., Donovan, K. A., Yuan, C. J., Nabet, B., Gero, T. W., Feru, F., Li, L., et al. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2019.12.006 · Cited by 275
Mannose-6-phosphate pathway: A review on its role in lysosomal function and dysfunction
Coutinho, M. F., Prata, M. J., & Alves, S. (2012) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2011.12.012 · Cited by 273
Protein S-guanylation by the biological signal 8-nitroguanosine 3′,5′-cyclic monophosphate
Sawa, T., Zaki, M. H., Okamoto, T., Akuta, T., Tokutomi, Y., Kim-Mitsuyama, S., Ihara, H., Kobayashi, A., Yamamoto, M., Fujii, S., et al. (2007) · Nature Chemical Biology · doi:10.1038/nchembio.2007.33 · Cited by 272
A molecular perspective of mammalian autophagosome biogenesis
Mercer, T. J., Gubas, A., & Tooze, S. A. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.r117.810366 · Cited by 265
Is resistance useless? Multidrug resistance and collateral sensitivity
Hall, M. D., Handley, M. D., & Gottesman, M. M. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.07.003 · Cited by 259
Crew, A. P., Raina, K., Dong, H., Qian, Y., Wang, J., Vigil, D., Serebrenik, Y. V., Hamman, B. D., Morgan, A., Ferraro, C., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00635 · Cited by 257
Self-citationStructural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex
Bussiere, D. E., Xie, L., Srinivas, H., Shu, W., Burke, A., Be, C., Zhao, J., Godbole, A., King, D., Karki, R. G., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-019-0411-6 · Cited by 257
Selective Autophagy and Xenophagy in Infection and Disease
Sharma, V., Verma, S., Seranova, E., Sarkar, S., & Kumar, D. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00147 · Cited by 247
Maniaci, C., Hughes, S. J., Testa, A., Chen, W., Lamont, D. J., Rocha, S., Alessi, D. R., Romeo, R., & Ciulli, A. (2017) · Nature Communications · doi:10.1038/s41467-017-00954-1 · Cited by 245
Bifunctional small molecules that mediate the degradation of extracellular proteins
Caianiello, D. F., Zhang, M., Ray, J. D., Howell, R. A., Swartzel, J. C., Branham, E. M. J., Chirkin, E., Sabbasani, V. R., Gong, A. Z., McDonald, D. M., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00851-1 · Cited by 244
Structure‐Based Design of a Macrocyclic PROTAC
Testa, A., Hughes, S. J., Lucas, X., Wright, J. E., & Ciulli, A. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201914396 · Cited by 242
Ohoka, N., Okuhira, K., Ito, M., Nagai, K., Shibata, N., Hattori, T., Ujikawa, O., Shimokawa, K., Sano, O., Koyama, R., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.768853 · Cited by 240
PRosettaC: Rosetta Based Modeling of PROTAC Mediated Ternary Complexes
Zaidman, D., Prilusky, J., & London, N. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00589 · Cited by 224
Development of Triantennary N-Acetylgalactosamine Conjugates as Degraders for Extracellular Proteins
Zhou, Y., Teng, P., Montgomery, N. T., Li, X., & Tang, W. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00146 · Cited by 221
Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation
Lv, L., Chen, P., Cao, L., Li, Y., Zeng, Z., Cui, Y., Wu, Q., Li, J., Wang, J.-H., Dong, M.-Q., et al. (2020) · eLife · doi:10.7554/elife.59994 · Cited by 215 · cited 1×
“Interestingly, similar results have now been published by the Winter (149) and Wang (150) groups.”
ResultChemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC)
Robb, C. M., Contreras, J. I., Kour, S., Taylor, M. A., Abid, M., Sonawane, Y. A., Zahid, M., Murry, D. J., Natarajan, A., & Rana, S. (2017) · Chemical Communications · doi:10.1039/c7cc03879h · Cited by 211
Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer
Rodriguez-Gonzalez, A., Cyrus, K., Salcius, M., Kim, K., Crews, C. M., Deshaies, R. J., & Sakamoto, K. M. (2008) · Oncogene · doi:10.1038/onc.2008.320 · Cited by 206
Self-citationATTEC: a potential new approach to target proteinopathies
Li, Z., Zhu, C., Ding, Y., Fei, Y., & Lu, B. (2020) · Autophagy · doi:10.1080/15548627.2019.1688556 · Cited by 206
In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application
Drummond, M. L., & Williams, C. I. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00872 · Cited by 199 · cited 1×
“(108) sampled a few rational methods for assessing ternary complexes using the MOE modeling package.”
MethodThe rise, fall and subsequent triumph of thalidomide: lessons learned in drug development
Rehman, W., Arfons, L. M., & Lazarus, H. M. (2011) · Therapeutic Advances in Hematology · doi:10.1177/2040620711413165 · Cited by 192
Phosphorylation-Inducing Chimeric Small Molecules
Siriwardena, S. U., Munkanatta Godage, D. N. P., Shoba, V. M., Lai, S., Shi, M., Wu, P., Chaudhary, S. K., Schreiber, S. L., & Choudhary, A. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c05537 · Cited by 190
Saenz, D. T., Fiskus, W., Qian, Y., Manshouri, T., Rajapakshe, K., Raina, K., Coleman, K. G., Crew, A. P., Shen, A., Mill, C. P., et al. (2017) · Leukemia · doi:10.1038/leu.2016.393 · Cited by 185
Self-citationCostales, M. G., Aikawa, H., Li, Y., Childs-Disney, J. L., Abegg, D., Hoch, D. G., Pradeep Velagapudi, S., Nakai, Y., Khan, T., Wang, K. W., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1914286117 · Cited by 185
Mannose 6-Phosphate Receptor Targeting and its Applications in Human Diseases
Gary-Bobo, M., Nirde, P., Jeanjean, A., Morere, A., & Garcia, M. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707782794005 · Cited by 184
Systematic approaches to identify E3 ligase substrates
Iconomou, M., & Saunders, D. N. (2016) · Biochemical Journal · doi:10.1042/bcj20160719 · Cited by 178
Sun, B., Fiskus, W., Qian, Y., Rajapakshe, K., Raina, K., Coleman, K. G., Crew, A. P., Shen, A., Saenz, D. T., Mill, C. P., et al. (2018) · Leukemia · doi:10.1038/leu.2017.207 · Cited by 178
Self-citationOttis, P., Palladino, C., Thienger, P., Britschgi, A., Heichinger, C., Berrera, M., Julien-Laferrière, A., Roudnicky, F., Kam‐Thong, T., Bischoff, J. R., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.9b00525 · Cited by 178
Ishoey, M., Chorn, S., Singh, N., Jaeger, M. G., Brand, M., Paulk, J., Bauer, S., Erb, M. A., Parapatics, K., Müller, A. C., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00969 · Cited by 177
Burslem, G. M., Song, J., Chen, X., Hines, J., & Crews, C. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b10320 · Cited by 176 · cited 1×
“For example, degradation of Epidermal Growth Factor Receptor (EGFR) and FMSLike Tyrosine kinase 3 (FLT-3) caused more sustained inhibition of their respective signaling pathways leading to decreased cell growth (17, 117).”
BackgroundSelf-citationAssessing Different E3 Ligases for Small Molecule Induced Protein Ubiquitination and Degradation
Ottis, P., Toure, M., Cromm, P. M., Ko, E., Gustafson, J. L., & Crews, C. M. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00485 · Cited by 176
Self-citationPROTAC-mediated degradation reveals a non-catalytic function of AURORA-A kinase
Adhikari, B., Bozilovic, J., Diebold, M., Schwarz, J. D., Hofstetter, J., Schröder, M., Wanior, M., Narain, A., Vogt, M., Dudvarski Stankovic, N., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-00652-y · Cited by 171
Buckley, D. L., & Crews, C. M. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307761 · Cited by 168
Self-citationDrummond, M. L., Henry, A., Li, H., & Williams, C. I. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00897 · Cited by 166 · cited 1×
“The Williams group has further refined their computational model using more constrained PROTAC conformations (110).”
BackgroundTanowitz, M., Hettrick, L. A., Revenko, A. S., Kinberger, G. A., Prakash, T. P., & Seth, P. P. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx960 · Cited by 165
Targeting Brd4 for cancer therapy: inhibitors and degraders
Duan, Y., Guan, Y., Qin, W., Zhai, X., Yu, B., & Liu, H. (2018) · MedChemComm · doi:10.1039/c8md00198g · Cited by 161
Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma
Chanan-Khan, A. A., Swaika, A., Paulus, A., Kumar, S. K., Mikhael, J. R., Rajkumar, S. V., Dispenzieri, A. A., & Lacy, M. Q. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.38 · Cited by 158
Bardoxolone conjugation enables targeted protein degradation of BRD4
Tong, B., Luo, M., Xie, Y., Spradlin, J. N., Tallarico, J. A., McKenna, J. M., Schirle, M., Maimone, T. J., & Nomura, D. K. (2020) · Scientific Reports · doi:10.1038/s41598-020-72491-9 · Cited by 154
An allosteric inhibitor of substrate recognition by the SCFCdc4 ubiquitin ligase
Orlicky, S., Tang, X., Neduva, V., Elowe, N. H., Brown, E., Sicheri, F., & Tyers, M. (2010) · Nature Biotechnology · doi:10.1038/nbt.1646 · Cited by 153
Mutant-selective degradation by BRAF-targeting PROTACs
Alabi, S., Jaime-Figueroa, S., Yao, Z., Gao, Y., Hines, J., Samarasinghe, K. T. G., Vogt, L., Rosen, N., & Crews, C. M. (2021) · Nature Communications · doi:10.1038/s41467-021-21159-7 · Cited by 152
Self-citationHeterobifunctional Molecules Induce Dephosphorylation of Kinases–A Proof of Concept Study
Yamazoe, S., Tom, J., Fu, Y., Wu, W., Zeng, L., Sun, C., Liu, Q., Lin, J. M., Lin, K., Fairbrother, W. J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01167 · Cited by 148
Testa, A., Lucas, X., Castro, G. V., Chan, K.-H., Wright, J. E., Runcie, A. C., Gadd, M. S., Harrison, W. T. A., Ko, E. J., Fletcher, D., et al. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b05807 · Cited by 146
Aghajan, M., Jonai, N., Flick, K. M., Fu, F., Luo, M., Cai, X., Ouni, I., Pierce, N. W., Tang, X., Lomenick, B., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1645 · Cited by 144
Design, synthesis and biological evaluation of nuclear receptor-degradation inducers
Itoh, Y., Kitaguchi, R., Ishikawa, M., Naito, M., & Hashimoto, Y. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.09.041 · Cited by 143
Functional characterization of a PROTAC directed against BRAF mutant V600E
Posternak, G., Tang, X., Maisonneuve, P., Jin, T., Lavoie, H., Daou, S., Orlicky, S. M., de Rugy, T. G., Caldwell, L., Chan, K., et al. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0609-7 · Cited by 140
DT2216—a Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas
He, Y., Koch, R., Budamagunta, V., Zhang, P., Zhang, X., Khan, S., Thummuri, D., Ortiz, Y. T., Zhang, X., Lv, D., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00928-9 · Cited by 139
Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins — A review
Yang, C., Qin, C., Bai, L., & Wang, S. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.04.001 · Cited by 131
Demizu, Y., Shibata, N., Hattori, T., Ohoka, N., Motoi, H., Misawa, T., Shoda, T., Naito, M., & Kurihara, M. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.09.041 · Cited by 128
Endogenous Nitrated Nucleotide Is a Key Mediator of Autophagy and Innate Defense against Bacteria
Ito, C., Saito, Y., Nozawa, T., Fujii, S., Sawa, T., Inoue, H., Matsunaga, T., Khan, S., Akashi, S., Hashimoto, R., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.10.024 · Cited by 121
Mayor-Ruiz, C., Jaeger, M. G., Bauer, S., Brand, M., Sin, C., Hanzl, A., Mueller, A. C., Menche, J., & Winter, G. E. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.07.013 · Cited by 119
A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL
Tong, B., Spradlin, J. N., Novaes, L. F. T., Zhang, E., Hu, X., Moeller, M., Brittain, S. M., McGregor, L. M., McKenna, J. M., Tallarico, J. A., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00348 · Cited by 118
Okuhira, K., Ohoka, N., Sai, K., Nishimaki-Mogami, T., Itoh, Y., Ishikawa, M., Hashimoto, Y., & Naito, M. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.03.019 · Cited by 118
Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer
Noblejas‐López, M. D. M., Nieto‐Jiménez, C., Burgos, M., Sango, M. G., Montero, J. C., Esparís-Ogando, A., Pandiella, A., Galán‐Moya, E. M., & Ocaña, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1387-5 · Cited by 112
Ohoka, N., Morita, Y., Nagai, K., Shimokawa, K., Ujikawa, O., Fujimori, I., Ito, M., Hayase, Y., Okuhira, K., Shibata, N., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.001091 · Cited by 111
Shibata, N., Miyamoto, N., Nagai, K., Shimokawa, K., Sameshima, T., Ohoka, N., Hattori, T., Imaeda, Y., Nara, H., Cho, N., et al. (2017) · Cancer Science · doi:10.1111/cas.13284 · Cited by 106
Ohoka, N., Nagai, K., Hattori, T., Okuhira, K., Shibata, N., Cho, N. J., & Naito, M. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.471 · Cited by 104
Lc3-associated phagocytosis—The highway to hell for phagocytosed microbes
Herb, M., Gluschko, A., & Schramm, M. (2020) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.04.016 · Cited by 103
Abruzzese, M. P., Bilotta, M. T., Fionda, C., Zingoni, A., Soriani, A., Vulpis, E., Borrelli, C., Zitti, B., Petrucci, M. T., Ricciardi, M. R., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0362-2 · Cited by 102
Bromodomain Drug Discovery – the Past, the Present, and the Future
Pervaiz, M., Mishra, P., & Günther, S. (2018) · The Chemical Record · doi:10.1002/tcr.201800074 · Cited by 96
Development of target protein-selective degradation inducer for protein knockdown
Itoh, Y., Ishikawa, M., Kitaguchi, R., Sato, S., Naito, M., & Hashimoto, Y. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.03.057 · Cited by 89
Structural Insights into PROTAC-Mediated Degradation of Bcl-xL
Chung, C., Dai, H., Fernández, E., Tinworth, C. P., Churcher, I., Cryan, J., Denyer, J. C., Harling, J. D., Konopacka, A., Queisser, M. A., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00266 · Cited by 89
Zhang, X., Thummuri, D., He, Y., Liu, X., Zhang, P., Zhou, D., & Zheng, G. (2019) · Chemical Communications · doi:10.1039/c9cc07217a · Cited by 86 · cited 1×
“In addition, BCL-2 is also spared from degradation in all cell types (62, 63, 115, 116).”
BackgroundPlasticity of tumor cell invasion: governance by growth factors and cytokines
Odenthal, J., Takes, R. P., & Friedl, P. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw098 · Cited by 86
Treatment of Alzheimer’s by PROTAC-Tau Protein Degradation
Kargbo, R. B. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00083 · Cited by 83
Rathod, D., Fu, Y., & Patel, K. R. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105039 · Cited by 78
Targeted deubiquitination rescues distinct trafficking-deficient ion channelopathies
Kanner, S. A., Shuja, Z., Choudhury, P., Jain, A., & Colecraft, H. M. (2020) · Nature Methods · doi:10.1038/s41592-020-00992-6 · Cited by 74
The therapeutic effect of the BRD4-degrading PROTAC A1874 in human colon cancer cells
Qin, A., Jin, H., Song, Y., Gao, Y. L., Chen, Y., Zhou, L.-N., Wang, S., & Lu, X. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03015-6 · Cited by 73
Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines
Zhang, X., He, Y., Zhang, P., Budamagunta, V., Lv, D., Thummuri, D., Yang, Y., Pei, J., Yuan, Y., Zhou, D., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112397 · Cited by 71
Antibody RING-Mediated Destruction of Endogenous Proteins
Ibrahim, A. F. M., Shen, L., Tatham, M. H., Dickerson, D. R., Prescott, A. R., Abidi, N., Xirodimas, D. P., & Hay, R. T. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.032 · Cited by 68
DeMars, K. M., Yang, C., Castro-Rivera, C. I., & Candelario-Jalil, E. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.02.096 · Cited by 66
Minko, T. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.08.008 · Cited by 66
Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases
He, X., Ros, S. D., Nelson, J. T., Zhu, X., Jiang, T., Barun, O., Jiang, S., Michellys, P., Iskandar, M., Espinola, S., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00258 · Cited by 57
Burslem, G. M., Ottis, P., Jaime‐Figueroa, S., Morgan, A. R., Cromm, P. M., Toure, M., & Crews, C. M. (2018) · ChemMedChem · doi:10.1002/cmdc.201800271 · Cited by 57
Self-citationOhoka, N., Ujikawa, O., Shimokawa, K., Sameshima, T., Shibata, N., Hattori, T., Nara, H., Cho, N., & Naito, M. (2018) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00567 · Cited by 57
Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
Ohoka, N., Shibata, N., Hattori, T., & Naito, M. (2016) · Current Cancer Drug Targets · doi:10.2174/1568009616666151112122502 · Cited by 55
Fu, Y., Rathod, D., & Patel, K. R. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112275 · Cited by 53
Targeted Degradation of Proteins Localized in Subcellular Compartments by Hybrid Small Molecules
Okuhira, K., Shoda, T., Omura, R., Ohoka, N., Hattori, T., Shibata, N., Demizu, Y., Sugihara, R., Ichino, A., Kawahara, H., et al. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.105569 · Cited by 52
Zhang, F., Wu, Z., Chen, P., Zhang, J., Wang, T., Zhou, J., & Zhang, H. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115228 · Cited by 51
Chimeric Molecules to Target Proteins for Ubiquitination and Degradation
Sakamoto, K. M. (2005) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(05)99054-x · Cited by 42
A kinetic proofreading model for bispecific protein degraders
Bartlett, D. W., & Gilbert, A. M. (2020) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-020-09722-z · Cited by 41
Lu, Q., Ding, X., Huang, T., Zhang, S., Li, Y., Xu, L., Chen, G., Ying, Y., Wang, Y., Feng, Z., et al. (2019) · PubMed · Cited by 35
Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
Mogollón, P., Díaz-Tejedor, A., Algarín, E. M., Paíno, T., Garayoa, M., & Ocio, E. M. (2019) · Cells · doi:10.3390/cells8111432 · Cited by 32
PROTAC-mediated degradation of KRAS protein for anticancer therapeutics
Kargbo, R. B. (2020) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00584 · Cited by 30
Okuhira, K., Demizu, Y., Hattori, T., Ohoka, N., Shibata, N., Kurihara, M., & Naito, M. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-3127-9_42 · Cited by 25
Targeted modulation of E3 ligases using engineered ubiquitin variants
LeBlanc, N., Mallette, E., & Zhang, W. (2020) · FEBS Journal · doi:10.1111/febs.15536 · Cited by 25
PROTEOSTASIS: A European Network to Break Barriers and Integrate Science on Protein Homeostasis
Dißmeyer, N., Coux, O., Rodríguez, M. S., & Barrio, R. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2019.01.007 · Cited by 23
Bifunctional Molecules beyond PROTACs
Conway, S. J. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00293 · Cited by 23
Inhibitors for E3 ubiquitin ligases
Lydeard, J. R., & Harper, J. W. (2010) · Nature Biotechnology · doi:10.1038/nbt0710-682 · Cited by 20
[Cereblon as a primary target of IMiDs].
Ito, T., & Handa, H. (2019) · PubMed · doi:10.11406/rinketsu.60.1013 · Cited by 7
8-Nitro-cGMP—A New Player in Antibacterial Autophagy
Rawet-Slobodkin, M., & Elazar, Z. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.12.006 · Cited by 5
SNIPER Peptide‐Mediated Degradation of Endogenous Proteins
Fan, X., & Wang, Y. T. (2015) · Current Protocols in Chemical Biology · doi:10.1002/9780470559277.ch140202 · Cited by 3
Cited by
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
Self-citationLenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation
Yamanaka, S., Furihata, H., Yanagihara, Y., Taya, A., Nagasaka, T., Usui, M., Nagaoka, K., Shoya, Y., Nishino, K., Yoshida, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40385-9 · Cited by 73
Structure, Activity, and Function of SETMAR Protein Lysine Methyltransferase
Tellier, M. (2021) · Life · doi:10.3390/life11121342 · Cited by 20
Metadata
- Authors
- Alabi, S. B., & Crews, C. M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 296
- Pages
- 100647
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W3153520238
- Cited by
- 261
- References
- 177
- FWCI
- 11.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.